medigraphic.com
ISSN 1729-519X (Print)

2022, Number 6

<< Back

Revista Habanera de Ciencias Médicas 2022; 21 (6)

Regulatory strategy for development ofQuimi-Hib®, a semi-synthetic conjugate vaccine against Haemophilus influenzae type b

Rodríguez SA, Hardy RE

Language: Spanish
References: 20
Page: 1-9
PDF size: 622.59 Kb.


ABSTRACT

Introduction: Quimi-Hib®, a Cuban vaccine obtained by chemical synthesis and unique in the world, required its own regulatory strategy because there is no guideline on the requirements for its production and control.
Objective: To characterize the regulatory strategy of the pre-launch phase of Quimi-Hib® in Cuba.
Material and Methods: Descriptive-retrospective study of the requirements for the approval of the Cuban vaccine. Seven strategic steps were established to cover current and future regulatory standards based on expert advice for decision making. The starting point was the WHO´s guideline, which applies to anti-Hib vaccines of natural origin.
Results: The regulatory strategy was developed based on the 15 recommendations of the aforementioned guideline, 11 of which were extrapolated to the Cuban vaccine and four of which were not, but served as the basis for the development of four requirements with similar rationale that apply to the semisynthetic vaccine.
Six additional requirements were added, three of which were requested from the Cuba's National Regulatory Authority and three of which were obtained from the available relevant literature. These 21 requirements complete the regulatory package, the result of the strategy developed for this vaccine and the subsequent approval for marketing authorization and commercialization.
Conclusions: The regulatory strategy compensates for the lack of specific guidelines for synthetic Haemophilus influenzae type b vaccines and thus contributed to the approval of the first vaccine of this type. The regulatory strategy is flexible because it includes update requirements throughout the vaccine life cycle, and expert consensus was considered in its development.


REFERENCES

  1. World Health Organization. Haemophilus influenzae type b (Hib) Vaccination Position Paper - September 2013. Weekly Epidemiol Record [Internet]. 2013 [Citado 20/05/2022];88(39):413-28. Disponible en: Disponible en: https://apps.who.int/iris/handle/ 10665/242126 1.

  2. World Health Organization. Recommendations for the production and control of Haemophilus influenzae type b conjugate vaccines. Technical Report Series, No. 897 annex [Internet]. Geneva: WHO; 2000 [Citado 20/05/2022]. Disponible en: Disponible en: https://www.who.int/publications/m/item/hib-conjugate-vaccines-annex-1-trs-no-89 7 2.

  3. Vera C. Synthesis of Haemophilus influenzae type a oligosaccharides for vaccine development [Tesis Maestría]. Milán: Universidad de Milán; 2020 [Citado 24/08/2022]. Disponible en: Disponible en: http://memoria.depositolegale.it/*/http://hdl.handle.net/ 2434/809196 3.

  4. Verez VG, Roy R. Oligosacáridos derivados de ribosa-ribitol-fosfato y vacunas que los contienen [Internet]. Patente WIPO(PCT) WO2001016146A1; 2001 [Citado 24/08/2022]. Disponible en: Disponible en: https://patents.google.com/patent/WO2001016146A1/es 4.

  5. ICH_Harmonized Tripartite Guideline. Q3C(R8) Impurities: guideline for residual solvents [Internet]. Ginebra: ICH; 2021 [Citado 20/05/2022]. Disponible en: Disponible en: https://www.ich.org 5.

  6. World Health Organization. Guidelines for the production and quality control of synthetic peptide vaccines. Technical Report Series, No. 889 annex 1 [Internet]. Geneva: WHO; 1999 [Citado20/05/2022]. Disponible en: Disponible en: https://www.who.int/publications/m 6.

  7. CECMED. Regulación M 83-15 Requisitos para el registro sanitario de productos biológicos de uso humano [Internet]. La Habana: MINSAP; 2015 [Citado 20/05/2022]. Disponible en: Disponible en: https://www.cecmed.cu 7.

  8. Zarei AE, Almehdar HA, Redwan EM. Hib Vaccines: Past, Present, and Future Perspectives. J Immunol Res [Internet]. 2016. [Citado 24/08/2022]:[Aprox. 2 p.]. Disponible en: http://dx.doi.org/10.1155/2016/7 2035878.

  9. Vérez Bencomo V. Vacuna contra el Haemophilus influenzae tipo b a partir de un antígeno sintético. En: Rojas Ochoa F. Vacunas. Cuba 1958-2008 [Internet].La Habana: Editorial Ciencias Médicas; 2011.pp.138-42.

  10. Walker C, Soulis T. Global Regulatory Strategy. En: Global Pharmaceutical and Biologics Regulatory Strategy. 2 ed [Internet]. EE.UU: Regulatory Affairs Professionals Society; 2020 [Citado 30/09/2022]. Disponible en: Disponible en: https://www.raps.org 10.

  11. World Health Organization. History of WHO [Internet]. Geneva: WHO ; 2022 [Citado 20/05/2022]. Disponible en: Disponible en: https://www.who.int/about/who-we-are/history 11.

  12. World Health Organization. Expert Committee on Biological Standardization [Internet]. Geneva: WHO ; 2022 [Citado 20/05/2022]. Disponible en: Disponible en: https://www.who.int/ groups/expert-committee-on-biological-standardization 12.

  13. Myers C, Pelletier M, CRB group. Behind every rapid response is a strong regulatory strategy [Internet]. Atlanta: Crbgroup; 2022 [Citado 30/09/2022]. Disponible en: Disponible en: https://www. crbgroup.com 13.

  14. Abdelhameed AS, Adams GG, Morris GA, Almutairi FM, Duvivier P, Conrath K, et al. A glycoconjugate of Haemophilus influenzae Type b capsular polysaccharide with tetanus toxoid protein: hydrodynamic properties mainly influenced by the carbohydrate. Sci Rep [Internet]. 2016;6:22208. Disponible en: http://doi.org/10.1038/srep2220814.

  15. Rodríguez A, Sánchez CA, Hardy E. Reglamentación para vacunas conjugadas contra el Haemophilus influenzae de tipo b, basadas en oligosacáridos sintéticos. Rev Cubana Far [Internet]. 2022 [Citado 19/07/2022];55(2):e838. Disponible en: Disponible en: http://www.revfarmacia.sld.cu/index.php/far/article/view/838 15.

  16. Lillo P, Rivera JD, Caro R. Proposición de estrategia regulatoria del hidrógeno para Chile [Internet]. Chile: Centro de Energía de la Pontificia Universidad Católica de Chile; 2020. [Citado 24/08/2022]. Disponible en: Disponible en: https://4echile.cl/wp-content/uploads/2020/05/Estrate gia-regulacion-nacional-H2.pdf 16.

  17. FDA. Guidance for Industry and Review Staff. Target Product Profile - A Strategic Development Process Tool [Internet]. EE UU: FDA; 2007 [Citado 24/08/2022]. Disponible en: Disponible en: http://www.fda.gov/cder/guidance /index.htm 17.

  18. European Medicines Agency. PRIME: Priority Medicines [Internet]. Amsterdam: EMA; 2020 [Citado 24/08/2022]. Disponible en: Disponible en: https://www.ema.eu/en/human-regulatory/research-development/prime-priority-medicines 18.

  19. López L, Egües LI, Pérez A, Galindo BM, Galindo MA, Resik S, et al. Experiencia cubana en inmunización, 1962-2016. Revista Panamericana de Salud Publica [Internet]. 2018;42:e34. Disponible en: https://doi.org/10.26633/RPSP.2018.3419.

  20. Rojas F. Salud y Salud Pública: Conceptualización. En: Rojas F, Silva D, eds. Salud y Salud Pública. Teoría y práctica. La Habana: Editorial Ciencias Médicas ; 2019.pp. 4-5.




2020     |     www.medigraphic.com